Teva (TEVA) CEO Richard Francis gets RSU grant and sells shares for tax

Rhea-AI Filing Summary

Teva Pharmaceutical Industries President and CEO Richard Francis reported multiple equity transactions on ordinary shares and restricted share units. He exercised 50,223 restricted share units, receiving the same number of ordinary shares at a price of $0.00 per share, as part of a prior equity grant.

On the same date, he received a new award of 136,736 restricted share units, each representing a right to one ordinary share or its cash value at settlement. He then sold 23,393 ordinary shares at a weighted average price of $32.4645 per share, with the shares sold at prices between $32.095 and $33.30 to cover tax withholding obligations under a pre-established Rule 10b5-1 trading plan.

Following these transactions, Francis held 1,148,212 ordinary shares directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Francis Richard D

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/04/2026		M		50,223	A	(2)	1,171,605	D
Ordinary Shares(1)	03/04/2026		S(3)		23,393(4)	D	$32.4645(5)	1,148,212	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	03/04/2026		M			50,223	(6)	(6)	Ordinary Shares(1)	50,223	$0	100,446	D
Restricted Share Units	(2)	03/04/2026		A		136,736		(7)	(7)	Ordinary Shares(1)	136,736	$0	136,736	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025.

4. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.095 to $33.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

6. Restricted share units were granted on March 4, 2024, with 50,223 vested on each of March 4, 2025 and March 4, 2026, and 50,223 vesting on each of March 4, 2027 and March 4, 2028.

7. Restricted share units were granted on March 4, 2026, with 34,184 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030.

	/s/ Dov Bergwerk as attorney-in-fact for Richard D. Francis	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did TEVA CEO Richard Francis report in this Form 4 filing?

Richard Francis reported equity award activity and a related share sale. He exercised 50,223 restricted share units into ordinary shares, received a new 136,736-unit restricted share award, and sold 23,393 ordinary shares in open-market transactions linked to tax withholding obligations.

How many TEVA shares did the CEO sell and at what price?

The CEO sold 23,393 ordinary shares of Teva. These sales occurred at a weighted average price of $32.4645 per share, with individual trades executed between $32.095 and $33.30, according to the detailed transaction price range disclosure.

Were Richard Francis’s TEVA share sales made under a 10b5-1 plan?

Yes, the reported sale was made under a Rule 10b5-1 trading plan. The footnotes state the plan was adopted on November 14, 2025, indicating the transactions followed a pre-arranged trading program rather than discretionary, same-day decisions.

Why did the TEVA CEO sell 23,393 ordinary shares?

The sale covered tax withholding from restricted share unit vesting. A footnote explains these 23,393 shares were required to be sold to satisfy tax obligations associated with the vesting of restricted share units previously granted to Richard Francis.

What new equity award did TEVA grant its CEO in this filing?

Richard Francis received 136,736 new restricted share units. The award was granted on March 4, 2026, with 34,184 units scheduled to vest on each of March 4, 2027, 2028, 2029, and 2030, providing multi-year equity-based compensation.

How many TEVA ordinary shares does the CEO hold after these transactions?

After the reported transactions, Francis held 1,148,212 ordinary shares directly. This figure reflects his position after exercising 50,223 restricted share units into shares and selling 23,393 shares in open-market transactions for tax withholding purposes.